These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1279 related items for PubMed ID: 18082216

  • 1. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F, CombAT Study Group.
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [Abstract] [Full Text] [Related]

  • 2. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
    Barkin J, Roehrborn CG, Siami P, Haillot O, Morrill B, Black L, Montorsi F, CombAT Study Group.
    BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
    [Abstract] [Full Text] [Related]

  • 3. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F, CombAT Study Group.
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [Abstract] [Full Text] [Related]

  • 4. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG, Barkin J, Tubaro A, Emberton M, Wilson TH, Brotherton BJ, Castro R.
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [Abstract] [Full Text] [Related]

  • 5. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.
    Becher E, Roehrborn CG, Siami P, Gagnier RP, Wilson TH, Montorsi F.
    Prostate Cancer Prostatic Dis; 2009 Apr; 12(4):369-74. PubMed ID: 19901936
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
    Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, Major-Walker K, Morrill BB, CombAT study group.
    Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
    [Abstract] [Full Text] [Related]

  • 8. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
    Montorsi F, Henkel T, Geboers A, Mirone V, Arrosagaray P, Morrill B, Black L.
    Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M, Ramsdell J, Young J, McNicholas T.
    J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [Abstract] [Full Text] [Related]

  • 12. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z.
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [Abstract] [Full Text] [Related]

  • 13. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia.
    Schulman CC, Lock TM, Buzelin JM, Boeminghaus F, Stephenson TP, Talja M, European Tamsulosin Study Group.
    J Urol; 2001 Oct; 166(4):1358-63. PubMed ID: 11547074
    [Abstract] [Full Text] [Related]

  • 14. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J.
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [Abstract] [Full Text] [Related]

  • 16. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.
    Haillot O, Fraga A, Maciukiewicz P, Pushkar D, Tammela T, Höfner K, Chantada V, Gagnier P, Morrill B.
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):302-6. PubMed ID: 21502969
    [Abstract] [Full Text] [Related]

  • 17. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA, McVary KT.
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [Abstract] [Full Text] [Related]

  • 18. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L.
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [Abstract] [Full Text] [Related]

  • 19. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M, Lukacs B, Matzkin H, Alcaraz A, Elhilali M, Vallancien G.
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [Abstract] [Full Text] [Related]

  • 20. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial.
    Roehrborn CG, Wilson TH, Black LK.
    J Urol; 2012 May; 187(5):1732-8. PubMed ID: 22425127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.